Shares of Vermillion, Inc. (NASDAQ: VRML) rallied more than 5% Tuesday on renewed speculation that the company could be a takeover target. Last week, the company announced that United States Patent and Trademark Office (USPTO) issued a notice of allowance for a patent entitled "Saposin D and Fam3C are Biomarkers for Alzheimer's Disease." The patent claims cover the biomarkers saposin D and Fam3c as well as combinations that include these biomarkers. Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. Stay tuned for more.
Full Disclosure: None.